News About: Pharm. Affairs
Will Sovaldi and Harvoni be registered for insurance benefit this June?
Due to the last year’s hepatitis C injection crisis at Dana Clinic, the health insurance benefit of Gilead Sciences’ Sovaldi Tab and Harvoni Tab have attracted attention of the industry.
According to the Ministry of ...
Massive original drugs’ patent walls will collapse for generic entry
Even in 2016, massive original drugs’ patents will collapse.
There are the total 11 original products expired in patent(based on substance patents) in 2016. Although none of them has an impact as huge as Baraclude wo...
KRW 13 trillion pharmaceutical sales this year, expected to slightly increase
This year, pharmaceutical sales of domestic pharmaceutical companies are expected to narrowly decrease to KRW 12.8 trillion.
Gi-dal Bae and Ji-yong Lee, researchers at Shinhan Investment Corp., announced the above th...
‘Celebrex’ developed the most for bioequivalently approved generics last year
A pharmaceutical product which was developed as generics by the most number of pharmaceutical companies was ‘Celebrex’ last year.
According to the Medipana News’ analysis result of the Ministry of Food and Drug Safet...
Viagra’s design dispute, “Although Pfizer acquired justification…
Over the blue diamond-shape ‘Viagra’s’ design and trademark rights, Pfizer Pharmaceuticals and Hanmi Pharm have had complicated ties on lawsuits.
First of all, there is a trial for injunction against infringement of ...
Antibiotic prescriptions were decreased by 24%, annually 5.45%, for the past 6 years
The last year’s antibiotic prescriptions of domestic medical institutions were recorded at KRW 1.0077 trillion, decreased by 23.9%, KRW 316.4 billion, compared to the year of 2010, 6 years ago. Its average annual decr...
Almagel excluded to be used as reflux esophagitis treatment
Since the ‘reflux esophagitis’ indication of almagate drugs, including Almagel(Yuhan Corporation), has been excluded since the 17th of the last month, the relevant suspension market has been worried.
In order to fill...
ARB-type antihypertensives in the down-turning market
The Big 4 ARB-type antihypertensives – Twynsta(Boehringer Ingelheim), Amosartan(Hanmi Pharm), Exforge(Novartis) and Sevikar(Daiichi Sankyo) – have shown decreases altogether.
According to the UBIST data on the 28th, ...
Will ‘Zemiglo’ handed to Daewoong change dynamics of the DPP-4 market?
As the domestic sales license of ‘Zemiglo,’ a domestic diabetes treatment which has been a hot potato since the beginning of this year, was passed to Daewoong Pharmaceutical, its future dynamic is expected to change.
...
High expectation on ‘Lynparza,’ BRCA-mutated ovarian cancer targeted treatment
‘Lynparza,’ a targeted therapy for ovarian cancer known for its low survival rate and high recurrence rate, was launched in Korea.
On the 26th, AstraZeneca Korea(hereinafter referring to AZ) announced the launch of ‘...
